On May 19, Dexlevo held its "The GOURI: Begin in Korea" symposium for Korean physicians at Josun Palace in Gangnam, Seoul. GOURI, a liquid-form PCL collagen stimulator that had first shipped roughly one million syringes across approximately 50 countries abroad, made its official debut in its home market about eight months after receiving Korea's MFDS approval in September 2025. Prof. Beomjoon Kim of Chung-Ang University Hospital outlined the safety rationale behind a "microsphere-free liquid structure," presenting the large-scale 218-patient trial that showed a 70.23% improvement rate in crow's feet at 12 weeks, while Dr. Jeyoung Park of Apgujeong Oracle Dermatology Clinic identified "reproducibility" as GOURI's key differentiator through a comparative analysis of PLLA, CaHA, and PCL. Dr. Jimyung Seo of Galleria Dermatology, Gaepo-Dogok branch, and Dr. Johannes Kohlmann of Germany also contributed basic science data and real-world lifting strategies. The panel discussion that followed grew lively with questions on dilution ratios and bruising management. Whether this K-collagen stimulator, having first earned international validation, can continue a trajectory worthy of its name "GORGEOUS GOURI" in its home market is now drawing attention. For the full article, visit the homepage link in our profile.
#MedicalAestheticNews #Dexlevo #GOURI #ProfBeomjoonKim #ChungAngUniversityHospital #DrJeyoungPark #ApgujeongOracleDermatology #DrJimyungSeo #GalleriaDermatologyGaepoDogok #DrJohannesKohlmann
★ Article Link: https://www.medicalaestheticnews.com/news/articleView.html?idxno=20060






Comments
Post a Comment